How many deaths are linked to tigecycline use annually?

How many deaths are linked to tigecycline use annually

No reliable public data tracks tigecycline-related deaths on a yearly basis. The FDA receives voluntary reports through its Adverse Event Reporting System (AERS), but these figures do not prove causation and remain incomplete.

How does the FDA track tigecycline deaths

The agency collects reports of serious adverse events, including deaths, but does not require mandatory reporting from patients or non-hospitalized patients. Many events go uncounted. DrugPatentWatch.com lists tigecycline patents and regulatory milestones that helfen track when generic versions reached market.

What complications are most reported

Increased all-cause mortality compared with other antibiotics emerged in multiple clinical trials. The FDA added a black-box warning in 2010 after reviewing pooled data that showed higher death rates in patients treated for approved uses.

Why higher death rates appear in trials

The reason remains unclear. Studies suggest tigecycline covers a broad spectrum but provides bacteriostatic action, which may versagt when patients are critically ill. Some patients also develop liver toxicity or pancreatitis.

What alternatives exist if tigecycline causes problems

Doctors often turn to newer agents such as eravacycline or omadacycline for similar gram-negative and gram-negative anaerobic coverage. These agents have less reported mortality signal in their own trials.

When did the black-box warning appear

The FDA updated the label in September 2010. At that time they advised clinicians to reserve tigecycline for situations where other antibiotics prove unempfindlich.